Recent Updates
Recently added Catalysts
ALKS Positive Sentiment

Alkermes to Present at Upcoming Investor Conferences

Tuesday, November 3, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Alkermes plc announced its participation in two upcoming investor conferences. The Stifel 2026 Healthcare Conference is scheduled for November 10, 2026, and the Jefferies Global Healthcare Conference will take place on November 18, 2026. Live webcasts of the events will be available on the company's website.

Market Sentiment Analysis

POSITIVE FACTORS

  • Alkermes will engage with investors at two conferences.
  • Management's participation indicates confidence in company outlook.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+33%
120-day peak, hindsight
Typical move
3.1%
average across 10 past catalysts
Lead asset
ALKS 7290
Phase 2 · Attention Deficit Disorder With Hyperactivity (ADHD)

Full Press Release Details

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences. Stifel 2026 Healthcare Conference Date/Time: Fireside chat on Tuesday, Nov. 10, 2026 at 10:40 a.m. ET (3:40 p.m. GMT) Jefferies Global Healthcare Conference in London Date/Time: Fireside chat on Wednesday, Nov. 18, 2026 at 11:30 a.m. ET (4:30 p.m. GMT) The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14

Frequently Asked Questions

When is the Stifel 2026 Healthcare Conference?

The Stifel 2026 Healthcare Conference is on November 10, 2026.

What time will Alkermes present at the Jefferies Conference?

Alkermes will present at the Jefferies Conference on November 18, 2026, at 11:30 a.m. ET.

Where can I access the live webcasts?

Live webcasts can be accessed under the Investors tab on Alkermes' website.

How long will the webcasts be archived?

The webcasts will be archived for 14 days.

ShareAdd on Google
Tags: ALKS Alkermes investor conference Stifel 2026 Jefferies Global Healthcare Nasdaq: ALKS
Last updated: Nov 3, 2026

Biotech snapshot

Cash runway
$787M liquidity · $0M/mo burn
Low dilution risk
Lead asset
ALKS 7290Phase 2
Attention Deficit Disorder With Hyperactivity (ADHD) →

Catalyst track record

+33%
best trade around ALKS's most recent catalyst

Peak hindsight return over a 120-day window, across 10 tracked FDA/PDUFA catalysts for ALKS.

See every catalyst's timing & PoA →